LIX1-like protein promotes liver cancer progression via miR-21-3p-mediated inhibition of fructose-1,6-bisphosphatase

Jie Zou,Xiaoyun Zhu,Dejuan Xiang,Yanqiu Zhang,Jie Li,Zhigui Su,Lingyi Kong,Hao Zhang
DOI: https://doi.org/10.1016/j.apsb.2021.02.005
IF: 14.903
2021-06-01
Acta Pharmaceutica Sinica B
Abstract:<p>Limb and CNS expressed 1 like (LIX1L) is over-expressed in several types of tumors. However, the function of LIX1L in glucose metabolism and hepatocellular carcinoma (HCC) progression remains elusive. Here we report that LIX1L is over-expressed in human HCC tissues, which predicts unfavorable prognosis. LIX1L deficiency <em>in vivo</em> significantly attenuated liver cancer initiation in mice. Functional studies indicated that LIX1L overexpression elevated proliferation, migratory, invasive capacities of HCC cells <em>in vitro</em>, and promoted liver cancer growth and metastasis <em>in vivo.</em> LIX1L knockdown up-regulated fructose-1,6-bisphosphatase (FBP1) expression to reduce glucose consumption as well as lactate production. Mechanistically, LIX1L increased miR-21-3p expression, which targeted and suppressed FBP1, thereby promoting HCC growth and metastasis. MiR-21-3p inhibitor could abrogate LIX1L induced enhancement of cell migration, invasion, and glucose metabolism. Inhibition of miR-21-3p suppressed tumor growth in an orthotopic tumor model. Our results establish LIX1L as a critical driver of hepatocarcinogenesis and HCC progression, with implications for prognosis and treatment.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?